ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

ImageneBio IncNASDAQ: IMA

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense declines year over year

Q1 FY2026 income tax expense of $10K fell 64.3% year over year, ahead of the -312.4% change in trailing-twelve-month income tax expense.

Context

  • Income tax expense amounted to 43.8% of revenue in FY2025, up 43.4 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -64.3% holds above the trailing-twelve-month pace of -312.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10K+103.6% QoQ
Last fiscal yearDec 2025
-$350K-2792.3% YoY
LTMMar 2026
-$325K-312.4% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-64.3%——
1 year-2792.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(350K) USD
Year-over-year change
-2792.3%

Income Tax Expense vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -312.4% is the lowest of 4, against a peer median of -11.7%.
IMA Competitors
Income Tax Expense for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CNTBConnect Biopharma Holdings LimitedFY2025$197K USD-11.7%-12.9%307.8%
IFRXInflaRx N.V.LTM Mar 2026€12.28K EUR+135.4%—41.9%
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD———
STROSutro Biopharma, Inc.LTM Mar 2026-$115K USD-104.9%—0.1%
IMAImageneBio IncLTM Mar 2026-$325K USD-312.4%——
Peer median (excluding IMA) —-11.7%-12.9%0.1%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.